Urolithin A Protects Against ALS Motor Dysfunction Through Mitochondrial Repair
Study shows pomegranate compound urolithin A improves motor function in ALS mice by activating cellular cleanup of damaged mitochondria.
Summary
Researchers found that urolithin A, a compound derived from pomegranates and berries, significantly improved motor function in ALS mice exposed to copper. The compound worked by activating mitophagy—the cellular process that removes damaged mitochondria. In SOD1-G93A transgenic mice (a standard ALS model), copper exposure worsened muscle weakness and motor neuron loss. However, six weeks of urolithin A treatment (50 mg/kg daily) restored mitochondrial energy production, reduced neuroinflammation, and improved muscle strength and coordination. The study used comprehensive behavioral tests, tissue analysis, and proteomics to demonstrate that urolithin A's benefits stem from repairing mitochondrial dysfunction—a key feature of ALS progression.
Detailed Summary
This groundbreaking study reveals that urolithin A, a natural compound found in pomegranates and berries, can significantly improve motor dysfunction in amyotrophic lateral sclerosis (ALS) by repairing damaged cellular powerhouses called mitochondria.
Researchers used SOD1-G93A transgenic mice, a well-established model of familial ALS, to investigate how copper exposure affects disease progression and whether urolithin A could provide therapeutic benefits. The team exposed mice to low-dose copper chloride (0.13 PPM) in drinking water for seven weeks, then treated half the group with urolithin A (50 mg/kg daily) for six additional weeks.
The results were striking. Copper exposure significantly worsened ALS symptoms, causing greater muscle weakness, coordination problems, and motor neuron loss in the spinal cord. However, urolithin A treatment dramatically reversed these effects. Mice receiving the compound showed improved performance on multiple motor function tests, including climbing, grip strength, and coordination tasks. Tissue analysis revealed that urolithin A reduced muscle atrophy and fibrosis while preserving motor neurons.
The key mechanism involves mitophagy—the cellular process that removes damaged mitochondria. Copper exposure disrupted this cleanup system, leading to accumulation of dysfunctional mitochondria, reduced ATP energy production, and increased oxidative damage. Urolithin A restored mitophagy by upregulating key proteins (Parkin, PINK1, LAMP1) while reducing harmful protein accumulation (P62). This mitochondrial repair translated into restored energy production and reduced neuroinflammation.
Proteomic analysis of spinal cord tissue confirmed that urolithin A normalized multiple mitochondria-related biological processes that were disrupted by copper exposure. The compound also reduced activation of inflammatory brain cells (astrocytes and microglia) that contribute to motor neuron damage in ALS.
These findings suggest urolithin A could be a promising therapeutic approach for ALS, particularly given its safety profile and availability as a dietary supplement. However, the study was conducted only in mice, and human trials would be needed to confirm clinical benefits.
Key Findings
- Urolithin A improved motor function in ALS mice by 50mg/kg daily for 6 weeks
- Copper exposure worsened ALS symptoms by disrupting mitochondrial cleanup (mitophagy)
- Treatment restored cellular energy production and reduced neuroinflammation
- Muscle strength and coordination significantly improved with urolithin A therapy
- Compound preserved motor neurons and reduced muscle atrophy in spinal cord
Methodology
Researchers used SOD1-G93A transgenic mice exposed to 0.13 PPM copper chloride for 7 weeks, followed by 6 weeks of urolithin A treatment (50 mg/kg/day). Comprehensive behavioral testing, histological analysis, proteomics, and biochemical assays were employed to assess motor function and underlying mechanisms.
Study Limitations
Study conducted only in mice using a specific genetic ALS model (SOD1-G93A). Human ALS is heterogeneous, and results may not translate to all ALS subtypes. Long-term safety and optimal dosing in humans require clinical trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.